Rezolute Announces Positive Results from the Phase 3 upLIFT Study in Tumor Hyperinsulinism

November 16, 2026  Source: drugdu 50

"/
On November 13, 2026, Rezolute (Nasdaq: RZLT) announced positive results from the open-label Phase 3 upLIFT study of ersodetug in tumor hyperinsulinism (tumor HI), with the primary efficacy endpoint achieved based on preliminary results from a November 5 data evaluation; full topline results for the completed study, including statistical analysis, are expected by mid-December 2026.
The primary endpoint is the proportion of patients achieving at least a 50% reduction from baseline in glucose infusion rate (GIR), a measure of intravenous glucose dependency. Statistical significance requires the lower bound of the 95% confidence interval to exceed 30%, equating to at least 9 responders (≥56%) among 16 participants. To date, 13 participants have met the responder criterion, including 12 who completely discontinued IV glucose; one participant who entered hospice and died of cancer progression is classified as a non-responder.
The 16 enrolled participants comprise four with non-islet cell tumors and 12 with insulin-secreting malignant islet cell tumors (insulinomas). Ersodetug has been well tolerated in the pivotal and extension phases, with no drug-related safety findings attributed to it. In the study, eligible patients requiring continuous IV glucose receive ersodetug 9 mg/kg weekly for 8 weeks as an add-on to standard of care.
Ersodetug is a fully human monoclonal antibody that binds allosterically to the insulin receptor to reduce receptor over-activation by insulin and related substances such as IGF-2, thereby improving hypoglycemia, and has the potential to treat refractory hypoglycemia across any form of HI. Founder and Chief Executive Officer Nevan Charles Elam said the company plans to advance both congenital HI and tumor HI into the approval process in 2027 and looks forward to discussions with the FDA in the first quarter of 2027.

Source: https://ir.rezolutebio.com/news/detail/389/rezolute-announces-positive-results-from-the-phase-3-uplift-study-in-tumor-hyperinsulinism

By editor
Share: 

your submission has already been received.

OK

Subscribe

Please enter a valid Email address!

Submit

The most relevant industry news & insight will be sent to you every two weeks.